- Home
- CLLS vs CABA Comparison
CLLS vs CABA Comparison
Compare CLLS & CABA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLLS
- CABA
- Stock Information
- Founded
- CLLS 1999
- CABA 2017
- Country
- CLLS France
- CABA United States
- Employees
- CLLS N/A
- CABA N/A
- Industry
- CLLS Biotechnology: Pharmaceutical Preparations
- CABA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CLLS Health Care
- CABA Health Care
- Exchange
- CLLS Nasdaq
- CABA Nasdaq
- Market Cap
- CLLS 148.1M
- CABA 118.8M
- IPO Year
- CLLS 2007
- CABA 2019
- Fundamental
- Price
- CLLS $1.26
- CABA $1.24
- Analyst Decision
- CLLS Buy
- CABA Strong Buy
- Analyst Count
- CLLS 3
- CABA 10
- Target Price
- CLLS $7.00
- CABA $24.80
- AVG Volume (30 Days)
- CLLS 840.4K
- CABA 873.1K
- Earning Date
- CLLS 03-13-2025
- CABA 05-14-2025
- Dividend Yield
- CLLS N/A
- CABA N/A
- EPS Growth
- CLLS N/A
- CABA N/A
- EPS
- CLLS N/A
- CABA N/A
- Revenue
- CLLS $49,217,000.00
- CABA N/A
- Revenue This Year
- CLLS $1.26
- CABA N/A
- Revenue Next Year
- CLLS N/A
- CABA N/A
- P/E Ratio
- CLLS N/A
- CABA N/A
- Revenue Growth
- CLLS 435.38
- CABA N/A
- 52 Week Low
- CLLS $1.14
- CABA $1.16
- 52 Week High
- CLLS $3.38
- CABA $19.04
- Technical
- Relative Strength Index (RSI)
- CLLS 43.15
- CABA 28.43
- Support Level
- CLLS $1.16
- CABA $1.16
- Resistance Level
- CLLS $1.33
- CABA $1.85
- Average True Range (ATR)
- CLLS 0.07
- CABA 0.14
- MACD
- CLLS 0.01
- CABA -0.04
- Stochastic Oscillator
- CLLS 46.15
- CABA 11.89
Stock Price Comparison Chart: CLLS vs CABA
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC, product candidates in other therapeutic indications.
About CABA Cabaletta Bio Inc.
Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies, and exploring their potential to provide a deep and durable, perhaps curative, treatment, for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) has the potential to be applied across a broad range of autoimmune diseases.